Humacyte, Inc. (HUMA)
Automate Your Wheel Strategy on HUMA
With Tiblio's Option Bot, you can configure your own wheel strategy including HUMA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HUMA
- Rev/Share 0.0589
- Book/Share 0.2741
- PB 9.5951
- Debt/Equity 0.4398
- CurrentRatio 3.6799
- ROIC -0.7628
- MktCap 407962970.0
- FreeCF/Share -0.7664
- PFCF -4.0479
- PE -4.4529
- Debt/Assets 0.0975
- DivYield 0
- ROE 2.8597
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | HUMA | H.C. Wainwright | -- | Buy | -- | $4 | May 14, 2025 |
| Reiterated | HUMA | H.C. Wainwright | -- | Buy | $12 | $15 | Dec. 20, 2024 |
News
Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
DURHAM, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that its abstract on the V007 Pivotal Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV™) in arteriovenous access for high-risk patients with end-stage renal disease was accepted for an oral presentation at the Society for Vascular Surgery Vascular Annual Meeting (VAM25).
Read More
Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Humacyte, Inc. (NASDAQ:HUMA ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Thomas Johnson - Director-Corporate Communications, LifeSci Advisors, IR Laura Niklason - Founder, President and Chief Executive Officer Dale Sander - Chief Financial Officer, Chief Corporate Development Officer and Treasurer BJ Scheessele - Chief Commercial Officer Conference Call Participants Ryan Zimmerman - BTIG Josh Jennings - TD Cowen Kristen Kluska - Cantor Fitzgerald Bruce Jackson - Benchmark Company Operator Good morning, ladies and gentlemen and welcome to the Humacyte's First Quarter Results Conference Call. Currently, all participants are in a listen-only mode.
Read More
Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Negative
Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.29 per share a year ago.
Read More
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
DURHAM, N.C., May 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended March 31, 2025, on Tuesday, May 13, 2025.
Read More
All You Need to Know About Humacyte, Inc. (HUMA) Rating Upgrade to Buy
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Humacyte, Inc. (HUMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript
Published: March 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Humacyte, Inc. (NASDAQ:HUMA ) Q4 2024 Earnings Conference Call March 27, 2025 8:30 AM ET Company Participants Thomas Johnson - Director, Corporate Communications, LifeSci Advisors, IR Laura Niklason - President and CEO Dale Sander - CFO and Chief Corporate Development Officer Conference Call Participants Josh Jennings - TD Cowen & Company Ryan Zimmerman - BTIG Vernon Bernardino - H.C. Wainwright Bruce Jackson - Benchmark Company Operator Good morning, ladies and gentlemen.
Read More
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
DURHAM, N.C., March 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the fourth quarter and year ended December 31, 2024, on Friday, March 28, 2025.
Read More
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $2.00 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about March 27, 2025, subject to the satisfaction of customary closing conditions. …
Read More
Wall Street Bulls Look Optimistic About Humacyte, Inc. (HUMA): Should You Buy?
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
In the most recent trading session, Humacyte, Inc. (HUMA) closed at $3.37, indicating a -1.75% shift from the previous trading day.
Read More
Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Patent provides coverage into 2040 for key aspects of the bioreactor manufacturing system – – Symvess, the acellular tissue engineered vessel, is manufactured in this patented system – DURHAM, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the issuance of a U.S. Patent covering key aspects of the manufacturing of Symvess (acellular tissue engineered vessel-tyod) and other bioengineered human tissues.
Read More
Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
– The FDA has authorized Humacyte to release commercial shipments – – Positive responses from surgeons and trauma centers to initial sales and marketing outreach – - 21 hospitals have already initiated the Value Analysis Committee (VAC) approval process – DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the commercial launch of Symvess (acellular tissue engineered vessel-tyod) for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and …
Read More
Humacyte, Inc. - Investors of Humacyte Stock Encouraged to Contact Kehoe Law Firm, P.C. - HUMA
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
PHILADELPHIA, PA / ACCESS Newswire / February 20, 2025 / Kehoe Law Firm, P.C. is investigating whether certain officers and directors of Humacyte, Inc. ("Humacyte") (NASDAQ:HUMA) breached their fiduciary duties by failing to manage Humacyte in an acceptable manner and whether Humacyte and its shareholders were harmed as a result.
Read More
About Humacyte, Inc. (HUMA)
- IPO Date 2020-12-01
- Website https://www.humacyte.com
- Industry Biotechnology
- CEO Dr. Laura E. Niklason M.D., Ph.D.
- Employees 218